Pfizer remains a strong buy as it reaffirms and raises its guidance, driven by operational growth of acquired assets at 18%. The company's robust pipeline, especially in obesity treatment and Vyndamax, supports growth beyond the 2028 loss of exclusivity period. Valuation metrics are attractive, with a P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield. Although risks like margin pressure and pricing reversals for Eliquis exist, Pfizer's cost management and pipeline momentum underpin a positive outlook.
The Dividend Harvesting Portfolio achieved a 45.8% return on investment, generating $3,289.51 in annual dividends from a $28,800 investment, with a yield of 7.83%. Recent portfolio additions include Pfizer, valued for its yield above 6% and low earni...
Pfizer shares trade at $28.77 with a 5.91% dividend yield and a 12-month price target of $32.72, implying 13.84% upside. The company reported strong Q2 2026 results, raised revenue guidance, and has a promising pipeline including Padcev and Metsera o...
